Keywords
Next-Generation Sequencing (NGS)
Diagnostic Accuracy
Actionable Mutations
Non-Small Cell Lung Cancer (NSCLC)
Metanalysis and Systematic review
Abstract
Introduction: Non-small cell lung cancer (NSCLC) is the most prevalent phenotype of pulmonary neoplasm. This study aims to review the efficacy of Next-generation sequencing (NGS) compared to other techniques for identifying actionable mutations in tissue tumor samples or circulating tumor DNA (ctDNA) blood samples from NSCLC patients eligible for systemic therapy. Methods and Analysis: We will identify eligible diagnostic test studies using a predefined search strategy in Medline and PubMed. We will extract individual study results to calculate the diagnostic performance values of the test, such as sensitivity, specificity, and predictive value. NGS’s diagnostic performance will be compared with techniques recommended by NCCN and ESMO guidelines. The review and meta-analysis will adhere to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA-P) guidelines. Discussion: Identifying actionable mutations in tumor samples is crucial for managing advanced NSCLC. NGS offers benefits by detecting multiple genetic alterations simultaneously, though its high cost and time requirements hinder widespread use. Our systematic review will evaluate NGS’s diagnostic accuracy and clinical benefits compared to other techniques, considering factors like test turnaround time. To address challenges such as the difficulty in obtaining detailed patient data and interpreting mutations of uncertain clinical significance, we will seek evidence from clinical studies and guidelines to provide comprehensive insights.
1. Yousefi M, Jalilian H, Heydari S, Seyednejad F, Mir N. Cost of lung cancer: a systematic review. Value Health Reg Issues. 2023 Jan 1;33:17–26. https://doi.org/10.1016/j.vhri.2022.07.007
2. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May 4;74(3):229–63. https://doi.org/10.3322/caac.21834
3. Bray F, Colombet M, Aitken J, Bardot A, Eser S, Galceran J, et al. Cancer incidence in five continents, vol. XII (IARC CancerBase No. 19) [Internet]. Lyon; 2023 [cited 2024 May 31]. Available from: https://ci5.iarc.who.int
4. Wood R, Taylor-Stokes G. Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage. BMC Cancer. 2019 Dec 8;19(1):214. https://doi.org/10.1186/s12885-019-5428-4
5. Ezeife DA, Morganstein BJ, Lau S, Law JH, Le LW, Bredle J, et al. financial burden among patients with lung cancer in a publically funded health care system. Clin Lung Cancer [Internet]. 2019 Jul 1;20(4):231–6. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1525730418303346
6. Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023 Apr;34(4):339–57.
7. Kristina Gregory N, Miranda Hughes O, Aisner DL, Akerley W, Bauman JR, Bruno DS, et al. NCCN guidelines version 3.2023 non-small cell lung cancer continue NCCN Guidelines Panel Disclosures [internet]. 2023. Available from: https://www.nccn.org/home/member-
8. Grodzka A, Knopik-Skrocka A, Kowalska K, Kurzawa P, Krzyzaniak M, Stencel K, et al. Molecular alterations of driver genes in non-small cell lung cancer: from diagnostics to targeted therapy. EXCLI J [Internet]. 2023 Jan 2;22:415–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/37346803
9. Nesline MK, Knight T, Colman S, Patel K. Economic burden of checkpoint inhibitor immunotherapy for the treatment of non–small cell lung cancer in US clinical practice. Clin Ther [Internet]. 2020 Sep 1;42(9):1682-1698.e7. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0149291820303283
10. Haslem DS, Van Norman SB, Fulde G, Knighton AJ, Belnap T, Butler AM, et al. A Retrospective analysis of precision medicine outcomes in patients with advanced cancer reveals improved progression-free survival without increased health care costs. J Oncol Pract. 2017 Feb 1;13(2):e108–19. https://doi.org/10.1200/JOP.2016.011486
11. Villaruz LC, Socinski MA, Weiss J. Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine. Front Oncol. 2023 Feb 1;13. https://doi.org/10.3389/fonc.2023.1124167
12. Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Annals of Oncology [Internet]. 2020 Nov 1;31(11):1491–505. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0923753420399713
13. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009 Dec 4;339(jul21 1):b2700–b2700.
14. Whiting PF. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011 Oct 18;155(8):529.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Jose Nicolás Tellez Castillo, Ana María Goyeneche, Ricardo Elias Bruges Maya, Raul Hernando Murillo Moreno, Oscar Andres Gamboa Garay